skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Rationale, characteristics, and clinical performance of the OsteoSponge®: a novel allograft for treatment of osseous defects



Review

(6724) Total Article Views


Authors: Miller LE, Jacofsky DJ, Kirker KR, Fitzpatrick KL, Juda GA, Block JE

Published Date April 2012 Volume 2012:4 Pages 9 - 17
DOI: http://dx.doi.org/10.2147/ORR.S29397

Larry E Miller1,2, David J Jacofsky3, Kelly R Kirker4, Kristin L Fitzpatrick5, Gregory A Juda6, Jon E Block2

1Miller Scientific Consulting, Arden, NC, USA; 2Jon Block Group, San Francisco, CA, USA; 3CORE Institute, Phoenix, AZ, USA; 4Center for Biofilm Engineering, Bozeman, MT, USA; 5Department of Biological Structure, University of Washington, Seattle, WA, USA; 6Bacterin International, Belgrade, MT, USA

Abstract: A variety of bone grafts and bone graft substitutes, each with distinctly different characteristics, is available to the orthopedic surgeon for various reconstructive procedures. However, adequate reconstruction of osseous defects remains a therapeutic challenge. Each bone graft option has a unique set of benefits and risks that must be considered in relation to the particular pathology, and to patient characteristics and comorbidities, in order to achieve the best possible outcome. The OsteoSponge® allograft consists of 100% demineralized human cancellous bone, with no additional carrier materials. The OsteoSponge is compressible, allowing precise graft placement in most osseous defects; subsequent expansion completely fills the void. The material is prepared using methods that preserve native growth factors, thereby promoting cellular ingrowth, proliferation, and ultimately osteogenesis. Preliminary evidence suggests that the OsteoSponge matrix is safe and effective when used in surgical treatment of osseous defects. This article describes the rationale for, and characteristics of, the OsteoSponge, and summarizes the results from preclinical and human studies.

Keywords: allograft, bone graft, demineralized bone, osseous defect, OsteoSponge



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Jon Block

An 8-week multimodal treatment program improves symptoms of knee osteoarthritis: a real-world multicenter experience
Analysis of postmarket complaints database for the iFuse SI Joint Fusion System®: a minimally invasive treatment for degenerative sacroiliitis and sacroiliac joint disruption
Axial lumbar interbody fusion: a 6-year single-center experience
Bridging the osteoarthritis treatment gap with the KineSpring Knee Implant System: early evidence in 100 patients with 1-year minimum follow-up
Clinical utility of ultrasound guidance for intra-articular knee injections: a review
Facet-sparing lumbar decompression with a minimally invasive flexible MicroBlade Shaver® versus traditional decompression: quantitative radiographic assessment
Facial fat grafting with a prototype injection control device
Percutaneous vertebral augmentation for painful osteolytic vertebral metastasis: a case report
Radiofrequency-targeted vertebral augmentation versus traditional balloon kyphoplasty: radiographic and morphologic outcomes of an ex vivo biomechanical pilot study
Radiofrequency-targeted vertebral augmentation versus traditional balloon kyphoplasty: radiographic and morphologic outcomes of an ex vivo biomechanical pilot study [Erratum]
Successful two-stage revision of a KineSpring® joint unloading implant: a case study
The KineSpring® Knee Implant System: an implantable joint-unloading prosthesis for treatment of medial knee osteoarthritis
TranS1 VEO system: a novel psoas-sparing device for transpsoas lumbar interbody fusion
TranS1 VEO system: a novel psoas-sparing device for transpsoas lumbar interbody fusion [Corrigendum]

Readers of this article also read: